Cardiovascular Disease, Schizophrenia
Conditions
Keywords
Schizophrenia, Cardiovascular disease, Premature mortality, Arteriosclerosis, Risk factor, Intervention, Treatment, Somatic morbidity
Brief summary
Schizophrenia is a severe mental illness associated with excess mortality and affecting nearly 1% of the population. The average life expectancy for patients diagnosed with schizophrenia has been 55-60 years through the last generations in Denmark, while the general population has over the same period of time experienced an increase in life expectancy. As a result, the standardized mortality rate for patients with schizophrenia has increased markedly over the last three decades and is currently a major public health concern. Causes of death are mainly cardiovascular disease and patients diagnosed with schizophrenia has a relative risk of cardiovascular disease that is about 2-fold higher than the general population.
Detailed description
Little is known about severe progression of premature coronary arteriosclerosis in patients suffering from schizophrenia. Coronary artery calcium score is a well-defined measure to predict cardiovascular disease events, however there has not yet been any attempt to investigate whether there is an association between coronary artery calcium score and premature morbidity and mortality in patients diagnosed with schizophrenia. The objective of this study is to investigate the progression of arteriosclerosis in patients with schizophrenia at different stages of the disease, and to offer and implement adequate treatment for these patients according to their somatic condition. This study will identify risk factors of somatic diseases in these patients, with specific focus on early diagnoses, prevention, intervention and treatment of arteriosclerosis in schizophrenic patients. The investigation is about the possibility of detecting any differences between developing arteriosclerosis in schizophrenia patients versus the general population, and how common risk factors are contributing to this process. The results of this study should provide important modifications in the clinical guidelines for treatment of patients diagnosed with schizophrenia.
Interventions
OTHERIllness history
Existing psychiatric and somatic diagnosis and treatment. Charlson co-morbidity Index.
OTHERMeasure of social conditions
A self-report questionnaire measuring social isolation, including relations to family and friends.
OTHERMeasure of psychiatric condition
This method measures symptom severity, therapeutic response and general improvement, suicidal ideation, cognitive insight and awareness of illness and need for treatment and the ability to relabel symptoms.
PROCEDURECardiovascular measurement
This procedure is used to detect early identification of cardiovascular disease progression.
Sponsors
Aalborg Psychiatric Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Participants with a diagnosis of F20 schizophrenia. * Informed statement of consent * Age \> 18
Exclusion criteria
* Incompetency to create stabile relation or make agreements * Pregnancy and also breastfeeding women * Participants with severe claustrophobia * Participants with lack of ability to cooperate with the planned study program.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| CT coronary angiography - a quantitative clinical measurement | 6 years | CT coronary angiography is a non-invasive procedure that uses simple CT-scan without contrast to measure coronary calcifications |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Charlson Co-morbidity index - Self-report questionnaire | 6 years | Measure of illness history with focus on which additional somatic or psychiatric diagnosis patients have. |
| Lubben Social Network Scale-6 (LSNS-6) - Self-report questionnaire | 6 years | The LSNS-6 is a self-report questionnaire measuring social isolation, including relations to family and friends. |
| Global Assessment of Functioning (GAF) - Clinical evaluation | 6 years | The GAF is a clinical evaluation of the patient's overall functioning level, including psychological, social and interpersonal, and occupational functioning of mental health-illness. |
| Positive and Negative Syndrome Scale (PANNS) - Clinical psychiatric evaluation | 6 years | The PANNS measures symptom severity in schizophrenia with focus on two distinct syndromes. The postive syndromes including productive symptoms, and the negative syndrome, including deficit features. |
| Clinical Global Impression Scale (CGI) - Clinical psychiatric evaluation | 6 years | The CGI is a measure of symptom severity, therapeutic response and general improvement. |
| Echocardiography - Clinical objective evaluation | 6 years | Echocardiography is a non-invasive procedure that uses ultrasound waves to generate live images of the patient's heart |
| Heart rate variability (HRV) - Clinical objective evaluation | 6 years | HRV is a non-invasive procedure that detects the function of the autonomic nervous system on the heart rhythm. |
| Existing psychiatric and somatic diagnosis and treatment - Self-report questionnaire | 6 years | Measure of illness history with focus on previous diagnosis and treatment |
| Toe brachial index (TBI) - Clinical objective evaluation | 6 years | TBP is a procedure that measures the relationship between the systolic blood pressure at the toe and the arm |
| Blood test - Clinical objective evaluation | 6 years | Blood test is used to identify biomedical markers. A volume of 20 ml will be needed from each patient. |
| Body Composition analysis (BCA) - Clinical objective evaluation | 6 years | Using a standard weight to measure body composition for each patient |
| CT-scan of upper abdomen (CTUA) - Clinical objective evaluation | 6 years | CTUA uses X-rays to produce cross-sectional images of the heart and liver |
| Cardiovascular magnetic resonance imaging(CMR) - Clinical objective evaluation | 6 years | CMR uses a strong magnetic field including radio waves to generate images of the heart |
| Adipose tissue biopsy - Clinical objective evaluation | 6 years | Adipose tissue biopsy is an invasive procedure that we use to understand the composition of fat acid for each patient in order to understand the correlation between fat acid and cardiovascular disease. |
| Urine sample - Objective clinical evaluation | 6 years | Urine sample measures the content of melatonin, which is a hormone that controls the natural cycle of sleeping and waking hours. |
| Pulmonary function test (PFT) - Clinical objective evaluation | 6 years | PFT also known as spirometry is a procedure that measures lung function |
Countries
Denmark
Contacts
Primary ContactJørgen Aagaard, MD
Backup ContactSvend E. Jensen, MD
Outcome results
None listed